Other languages Applied Genetic Technologies Corporation

Equities

AGTC

US03820J1007

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

British Investor Syncona Closes Acquisition of US Biotech Applied Genetic Technologies	22-12-01
Syncona Limited, a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation.	22-11-29
Applied Genetic Technologies Says Syncona Extends Tender Offer Through Wednesday	22-11-29
Syncona Extends Offer Period For $24 Million Takeover of Applied Genetic Technologies	22-11-29
Applied Genetic Technologies Corporation Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-21
Sector Update: Health Care Stocks Pacing Monday Markets as Defensive Sectors Shine	22-10-24
Sector Update: Health Care Stocks Pacing Monday Markets Advance	22-10-24
Applied Genetic Technologies Shares Soar After Company Agrees to Sell to Syncona for $23.5 Million	22-10-24
Applied Genetic Technologies Agrees to Sell to Syncona for $23.5 Million Through Tender Offer	22-10-24
Syncona To Launch $24 Million Takeover Offer For Applied Genetic Technologies	22-10-24
Applied Genetic Technologies Corporation Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-27
Applied Genetic Technologies Receives Favorable FDA Opinion for Manufacturing Facility	22-07-26
AGTC Receives Positive Type C Meeting Feedback from the Fda for the Company's Design and Operating Procedures of Its Planned cGMP Manufacturing Facility	22-07-26
Applied Genetic Technologies Prices $10 Million Public Offering	22-07-13
Applied Genetic Technologies Proposes Underwritten Public Offering -- Shares Down 29% After-Hours	22-07-12
Applied Genetic Technologies Corporation Announces Executive Appointments	22-06-08
Applied Genetic Technologies Sees 'Positive' Interim Data From Trial of AGTC-501 to Treat Retinitis Pigmentosa; Shares Rise	22-05-16
Applied Genetic Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-16
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa	22-05-16
Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting	22-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Applied Genetic Technologies Corporation

Equities

AGTC

US03820J1007

Other languages

Filters